Repurposing: A Review of a Cost-Effective and Time-Saving Drug Discovery
DOI:
https://doi.org/10.5281/SJCMS2026.1.1.28Keywords:
Drug repurposing; Drug discovery; Drug repositioningAbstract
Drug repurposing is a faster and safer approach in drug discovery that involves investigating already approved and marketed drugs for the treatment of conditions different from those for which they were originally prescribed, making it a cost-effective strategy. This review highlights both classical examples of drug repurposing, such as aspirin, dexamethasone, and propranolol, as well as recent applications, including therapies for COVID-19 and treatments for rare diseases. The evolution from traditional drug discovery methods to computational approaches, encompassing artificial intelligence, biological networks, transcriptomics, and literature mining, is explored. These approaches facilitate rapid screening, drug-disease network analysis, and other processes that enhance the efficiency and quality of drug discovery outcomes. Our findings emphasize how cutting-edge computational techniques, when integrated with established pharmacological knowledge, can expand therapeutic options across a wide spectrum of diseases, including neurological, infectious, cancer-related, and rare conditions. Drug repurposing thus represents a valuable resource for the medical field, offering the potential to enrich the drug market through computer-based and AI-assisted screening, supported by experimental and clinical research to validate and bring old drugs to new therapeutic applications.
References
[1] Rudrapal M, Shubham K, Jadhav A. Drug Repurposing (DR): An Emerging Approach in Drug Discovery, 2020. https://doi.org/10.5772/intechopen.93193.
[2] Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, et al. Drug repurposing: Progress, challenges and recommendations. Nat Rev Drug Discov 2018;18:41–58. https://doi.org/10.1038/nrd.2018.168.
[3] Singh N, Vayer P, Tanwar S, Poyet J-L, Tsaioun K, Villoutreix BO. Drug discovery and development: introduction to the general public and patient groups. Frontiers in Drug Discovery 2023;3. https://doi.org/10.3389/fddsv.2023.1201419.
[4] Jarada T, Rokne J, Alhajj R. A Review of Computational Drug Repositioning: Strategies, Approaches, Opportunities, Challenges, and Directions. J Cheminform 2020;12:1–23. https://doi.org/10.1186/s13321-020-00450-7.
[5] Shegokar R. Chapter 2 - Preclinical testing—Understanding the basics first. In: Shegokar R, editor. Drug Delivery Aspects, Elsevier; 2020, p. 19–32. https://doi.org/https://doi.org/10.1016/B978-0-12-821222-6.00002-6.
[6] Erhirhie EO, Ihekwereme CP, Ilodigwe EE. Advances in acute toxicity testing: Strengths, weaknesses and regulatory acceptance. Interdiscip Toxicol 2018;11:5–12. https://doi.org/10.2478/intox-2018-0001.
[7] Kandi V, Vadakedath S. Clinical Trials and Clinical Research: A Comprehensive Review. Cureus 2023. https://doi.org/10.7759/cureus.35077.
[8] Van Norman GA. Drugs, Devices, and the FDA: Part 1: An Overview of Approval Processes for Drugs. JACC Basic Transl Sci 2016;1:170–9. https://doi.org/10.1016/j.jacbts.2016.03.002.
[9] Hua Y, Dai X, Xu Y, Xing G, Liu H, Lu T, et al. Drug repositioning: Progress and challenges in drug discovery for various diseases. Eur J Med Chem 2022;234. https://doi.org/10.1016/j.ejmech.2022.114239.
[10] Kulkarni VS, Alagarsamy V, Solomon VR, Jose PA, Murugesan S. Drug Repurposing: An Effective Tool in Modern Drug Discovery. Russ J Bioorg Chem 2023;49:157–66. https://doi.org/10.1134/S1068162023020139.
[11] Salvad M, Diluca M, Gardoni F. Biomedicine & Pharmacotherapy An update on drug repurposing in Parkinson ’ s disease : Preclinical and clinical considerations 2025;183. https://doi.org/10.1016/j.biopha.2025.117862.
[12] Dézsi L, Vécsei L. Safinamide for the treatment of Parkinson’s disease. Expert Opin Investig Drugs 2014;23:729–42. https://doi.org/10.1517/13543784.2014.897694.
[13] Entzeroth M, Ratty A. Monoamine Oxidase Inhibitors—Revisiting a Therapeutic Principle. Open Journal of Depression 2017;6:31–68. https://doi.org/10.4236/ojd.2017.62004.
[14] Patrono C, Rocca B. Aspirin at 120: Retiring, recombining, or repurposing? Res Pract Thromb Haemost 2021;5:e12516. https://doi.org/10.1002/rth2.12516.
[15] Abdelsayed M, Kort EJ, Jovinge S, Mercola M. Repurposing drugs to treat cardiovascular disease in the era of precision medicine. Nat Rev Cardiol 2022;19:751–64. https://doi.org/10.1038/s41569-022-00717-6.
[16] Onesti G, Schwartz AB, Kim KE, Pax-Martinez V, Swartz C. Antihypertensive Effect of Clonidine. n.d.
[17] Ming S, Mulvey, Mohanty, Patel. Safety and efficacy of clonidine and clonidine extended-release in the treatment of children and adolescents with attention deficit and hyperactivity disorders. Adolesc Health Med Ther 2011:105. https://doi.org/10.2147/ahmt.s15672.
[18] Chakraborty C, Sharma AR, Bhattacharya M, Agoramoorthy G, Lee SS. The Drug Repurposing for COVID-19 Clinical Trials Provide Very Effective Therapeutic Combinations: Lessons Learned From Major Clinical Studies. Front Pharmacol 2021;12. https://doi.org/10.3389/fphar.2021.704205.
[19] Rajaiah R, Abhilasha K V, Shekar MA, Vogel SN, Vishwanath BS. Evaluation of mechanisms of action of re-purposed drugs for treatment of COVID-19. Cell Immunol 2020;358:104240. https://doi.org/https://doi.org/10.1016/j.cellimm.2020.104240.
[20] Liesienė J, Baniukaitiene O, Minseviciene I. Cellulose-Based Scaffolds with Prolonged Dexamethasone Release for Bone Tissue Engineering. Molecules 2025;30. https://doi.org/10.3390/molecules30132760.
[21] Rosenberg AS. From mechanism to resistance–changes in the use of dexamethasone in the treatment of multiple myeloma. Leuk Lymphoma 2023;64:283–91. https://doi.org/10.1080/10428194.2022.2136950.
[22] Ropper AH. The “Poison Chair” Treatment for Multiple Sclerosis. New England Journal of Medicine 2012;367:1149–50. https://doi.org/10.1056/nejme1209169.
[23] Bresciani G, Manai F, Davinelli S, Tucci P, Saso L, Amadio M. Novel potential pharmacological applications of dimethyl fumarate—an overview and update. Front Pharmacol 2023;14. https://doi.org/10.3389/fphar.2023.1264842.
[24] Mrowietz U, Szepietowski JC, Loewe R, van de Kerkhof P, Lamarca R, Ocker WG, et al. Efficacy and safety of LAS41008 (dimethyl fumarate) in adults with moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, Fumaderm®- and placebo-controlled trial (BRIDGE). British Journal of Dermatology 2017;176:615–23. https://doi.org/10.1111/bjd.14947.
[25] Lanz J, Biniaz-harris N, Kuvaldina M, Jain S, Lewis K, Fallon BA. Disulfiram : Mechanisms , Applications , and Challenges 2023.
[26] Bilska-wilkosz A, Magdalena G, Iciek M. Inactivation of Aldehyde Dehydrogenase by Disulfiram in the Presence and Absence of Lipoic Acid or Dihydrolipoic Acid : An in Vitro Study 2019.
[27] Choi SA, Choi JW, Wang K-C, Phi JH, Lee JY, Park KD, et al. Disulfiram modulates stemness and metabolism of brain tumor initiating cells in atypical teratoid/rhabdoid tumors. Neuro Oncol 2015;17:810–21. https://doi.org/10.1093/neuonc/nou305.
[28] Beaudry A, Jacques-Ricard S, Darracq A, Sgarioto N, Garcia A, García TR, et al. Repurposing disulfiram, an alcohol-abuse drug, in neuroblastoma causes KAT2A downregulation and in vivo activity with a water/oil emulsion. Sci Rep 2023;13. https://doi.org/10.1038/s41598-023-43219-2.
[29] Heimbürger SM, Brønden A, Johansen NJ, Dejgaard TF, Vilsbøll T, Knop FK. The efficacy and safety of exenatide once weekly in patients with type 2 diabetes. Expert Opin Pharmacother 2019;20:501–10. https://doi.org/10.1080/14656566.2019.1571040.
[30] Su N, Li Y, Xu T, Li L, Kwong JS-W, Du H, et al. Exenatide in obese or overweight patients without diabetes: A systematic review and meta-analyses of randomized controlled trials. Int J Cardiol 2016;219:293–300. https://doi.org/10.1016/j.ijcard.2016.06.028.
[31] Warner DS, Domino EF. CLASSIC PAPERS REVISITED Taming the Ketamine Tiger. vol. 113. 2010.
[32] Wei Y, Chang L, Hashimoto K. A historical review of antidepressant effects of ketamine and its enantiomers. Pharmacol Biochem Behav 2020;190:172870. https://doi.org/https://doi.org/10.1016/j.pbb.2020.172870.
[33] Carboni E, Carta AR, Carboni E, Novelli A. Repurposing Ketamine in Depression and Related Disorders: Can This Enigmatic Drug Achieve Success? Front Neurosci 2021;15. https://doi.org/10.3389/fnins.2021.657714.
[34] Das J. Repurposing of Drugs–The Ketamine Story. J Med Chem 2020;63:13514–25. https://doi.org/10.1021/acs.jmedchem.0c01193.
[35] Zhu H, Jia Z, Li YR, Danelisen I. Molecular mechanisms of action of metformin: latest advances and therapeutic implications. Clin Exp Med 2023;23:2941–51. https://doi.org/10.1007/s10238-023-01051-y.
[36] Saraei P, Asadi I, Kakar MA, Moradi-Kor N.
The beneficial effects of metformin on cancer prevention and therapy: a comprehensive review of recent advances
. Cancer Manag Res 2019;Volume 11:3295–313. https://doi.org/10.2147/CMAR.S200059.[37] Lord SR, Harris AL. Is it still worth pursuing the repurposing of metformin as a cancer therapeutic? Br J Cancer 2023;128:958–66. https://doi.org/10.1038/s41416-023-02204-2.
[38] Li B, Zhou P, Xu K, Chen T, Jiao J, Wei H, et al. Metformin induces cell cycle arrest, apoptosis and autophagy through ROS/JNK signaling pathway in human osteosarcoma. Int J Biol Sci 2020;16:74–84. https://doi.org/10.7150/ijbs.33787.
[39] Huynh TYL, Oscilowska I, Szoka L, Piktel E, Baszanowska W, Bielawska K, et al. Metformin Induces PRODH/POX-Dependent Apoptosis in Breast Cancer Cells. Front Mol Biosci 2022;9. https://doi.org/10.3389/fmolb.2022.869413.
[40] Löfmark S, Edlund C, Nord CE. Metronidazole Is Still the Drug of Choice for Treatment of Anaerobic Infections. Clinical Infectious Diseases 2010;50:S16–23. https://doi.org/10.1086/647939.
[41] Giglio J, Dematteis S, Fernández S, Cerecetto H, Rey A. Synthesis and evaluation of a new 99mTc(I)-tricarbonyl complex bearing the 5-nitroimidazol-1-yl moiety as potential hypoxia imaging agent. J Labelled Comp Radiopharm 2014;57:403–9. https://doi.org/10.1002/jlcr.3195.
[42] Ahmadi H, Heydari M, Abdouss M, Jamalpoor Z, Fathi-karkan S, Rahdar A, et al. Metronidazole delivery strategies: Optimizing cancer therapy through novel approaches for enhanced delivery, cytotoxicity, and side effect reduction. European Journal of Medicinal Chemistry Reports 2024;12:100202. https://doi.org/https://doi.org/10.1016/j.ejmcr.2024.100202.
[43] Sarna JR, Furtado S, Brownell AKW. Neurologic complications of metronidazole. Canadian Journal of Neurological Sciences 2013;40:768–76. https://doi.org/10.1017/S0317167100015870.
[44] Suparuj Lueangarun RP. Efficacy and Safety of Oral Minoxidil 5 mg Once Daily in the Treatment of Male Patients with Androgenetic Alopecia: An Open-Label and Global Photographic Assessment n.d. https://doi.org/10.6084/m9.figshare.12937661.
[45] Fukushiro-Lopes D, Hegel AD, Russo A, Senyuk V, Liotta M, Beeson GC, et al. Repurposing Kir6/SUR2 Channel Activator Minoxidil to Arrests Growth of Gynecologic Cancers. Front Pharmacol 2020;11. https://doi.org/10.3389/fphar.2020.00577.
[46] Cuesta AM, Gallardo-Vara E, Casado-Vela J, Recio-Poveda L, Botella LM, Albiñana V. The Role of Propranolol as a Repurposed Drug in Rare Vascular Diseases. Int J Mol Sci 2022;23. https://doi.org/10.3390/ijms23084217.
[47] Sommers Smith ~ SK, Dennis ND, Smith M. BETA BLOCKADE INDUCES APOPTOSIS IN CULTURED CAPILLARY ENDOTHELIAL CELLS. vol. 38. 2002.
[48] Storch CH, Hoeger PH. Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action. British Journal of Dermatology 2010;163:269–74. https://doi.org/10.1111/j.1365-2133.2010.09848.x.
[49] Sánchez-Carpintero I, Ruiz-Rodriguez R, López-Gutiérrez JC. Propranolol in the treatment of infantile hemangioma: Clinical effectiveness, risks, and recommendations. Actas Dermosifiliogr 2011;102:766–79. https://doi.org/10.1016/j.ad.2011.05.003.
[50] Léauté-Labrèze C, Hoeger P, Mazereeuw-Hautier J, Guibaud L, Baselga E, Posiunas G, et al. A Randomized, Controlled Trial of Oral Propranolol in Infantile Hemangioma. New England Journal of Medicine 2015;372:735–46. https://doi.org/10.1056/nejmoa1404710.
[51] Wooltorton E. Osteoporosis treatment: Raloxifene (Evista) and stroke mortality. CMAJ Canadian Medical Association Journal 2006;175:147–8. https://doi.org/10.1503/cmaj.060781.
[52] Iaconis D, Bordi L, Matusali G, Talarico C, Manelfi C, Cesta MC, et al. Characterization of raloxifene as a potential pharmacological agent against SARS-CoV-2 and its variants. Cell Death Dis 2022;13. https://doi.org/10.1038/s41419-022-04961-z.
[53] Leandro MJ, Becerra-Fernandez E. B-cell therapies in established rheumatoid arthritis. Best Pract Res Clin Rheumatol 2011;25:535–48. https://doi.org/https://doi.org/10.1016/j.berh.2011.10.005.
[54] Mok CC. Rituximab for the treatment of rheumatoid arthritis: An update. Drug Des Devel Ther 2013;8:87–100. https://doi.org/10.2147/DDDT.S41645.
[55] Rastetter W, Molina A, White C. Rituximab: Expanding Role in Therapy for Lymphomas and Autoimmune Diseases. Annu Rev Med 2004;55:477–503. https://doi.org/10.1146/annurev.med.55.091902.104249.
[56] Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, et al. Drug repurposing: Progress, challenges and recommendations. Nat Rev Drug Discov 2018;18:41–58. https://doi.org/10.1038/nrd.2018.168.
[57] Howell A, Howell SJ. Tamoxifen evolution. Br J Cancer 2023;128:421–5. https://doi.org/10.1038/s41416-023-02158-5.
[58] Jordan VC. Tamoxifen: A most unlikely pioneering medicine. Nat Rev Drug Discov 2003;2:205–13. https://doi.org/10.1038/nrd1031.
[59] Quirke VM. Tamoxifen from failed contraceptive pill to best-selling breast cancer medicine: A case-study in pharmaceutical innovation. Front Pharmacol 2017;8. https://doi.org/10.3389/fphar.2017.00620.
[60] Liu Z, Shi HY, Nawaz Z, Zhang M. Tamoxifen induces the expression of maspin through estrogen receptor-α. Cancer Lett 2004;209:55–65. https://doi.org/https://doi.org/10.1016/j.canlet.2003.11.018.
[61] Amare GG, Meharie BG, Belayneh YM. A drug repositioning success: The repositioned therapeutic applications and mechanisms of action of thalidomide. Journal of Oncology Pharmacy Practice 2021;27:673–8. https://doi.org/10.1177/1078155220975825.
[62] Tian J, Zhang M, Jin M, Zhang F, Chu Q, Wang X, et al. Repurposed Tocilizumab in Patients with Severe COVID-19. The Journal of Immunology 2021;206:599–606. https://doi.org/10.4049/jimmunol.2000981.
[63] Chaudhuri S, Symons JA, Deval J. Innovation and trends in the development and approval of antiviral medicines: 1987–2017 and beyond. Antiviral Res 2018;155:76–88. https://doi.org/10.1016/j.antiviral.2018.05.005.
[64] Broder S. The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. Antiviral Res 2010;85:1–18. https://doi.org/10.1016/j.antiviral.2009.10.002.
[65] Chung CCY, Chu ATW, Chung BHY. Rare disease emerging as a global public health priority. Front Public Health 2022;10. https://doi.org/10.3389/fpubh.2022.1028545.
[66] van Eeghen AM, Bruining H, Wolf NI, Bergen AA, Houtkooper RH, van Haelst MM, et al. Personalized medicine for rare neurogenetic disorders: can we make it happen? Cold Spring Harb Mol Case Stud 2022;8:1–14. https://doi.org/10.1101/mcs.a006200.
[67] Rudrapal M. Drug Repurposing (DR): An Emerging Approach in Drug Discovery. In: Badria F, editor. Drug Repurposing - Hypothesis, Molecular Aspects and Therapeutic Applications, London: IntechOpen; 2020. https://doi.org/10.5772/intechopen.93193.
[68] Hauser AS, Attwood MM, Rask-Andersen M, Schiöth HB, Gloriam DE. Trends in GPCR drug discovery: New agents, targets and indications. Nat Rev Drug Discov 2017;16:829–42. https://doi.org/10.1038/nrd.2017.178.
[69] Habib M, Lalagkas PN, Melamed RD. Mapping drug biology to disease genetics to discover drug impacts on the human phenome. Bioinformatics Advances 2024;4. https://doi.org/10.1093/bioadv/vbae038.
[70] Aggarwal S, Verma SS, Aggarwal S, Gupta SC. Drug repurposing for breast cancer therapy: Old weapon for new battle. Semin Cancer Biol 2021;68:8–20. https://doi.org/10.1016/j.semcancer.2019.09.012.
[71] Previtali R, Prontera G, Alfei E, Nespoli L, Masnada S, Veggiotti P, et al. Paradigm shift in the treatment of tuberous sclerosis: Effectiveness of everolimus. Pharmacol Res 2023;195:106884. https://doi.org/10.1016/j.phrs.2023.106884.
[72] Juvet SC, Hwang DI, Downey GP. Rare lung diseases I - Lymphangioleiomyomatosis. Can Respir J 2006;13:375–80. https://doi.org/10.1155/2006/696573.
[73] Koul PA, Mehfooz N. Sirolimus in lymphangioleiomyomatosis: A case in point for research in “orphan” diseases. Lung India 2019;36:353–5. https://doi.org/10.4103/lungindia.lungindia_280_19.
[74] Bissler JJ, Mccormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, et al. NIH Public Access 2012;358:140–51. https://doi.org/10.1056/NEJMoa063564.Sirolimus.
[75] Li YY, Jones SJM. Drug repositioning for personalized medicine. Genome Med 2012;4. https://doi.org/10.1186/gm326.
[76] Pessetto ZY, Chen B, Alturkmani H, Hyter S, Flynn CA, Baltezor M, et al. In silico and in vitro drug screening identifies new therapeutic approaches for Ewing sarcoma. Oncotarget 2017;8:4079–95. https://doi.org/10.18632/oncotarget.13385.
[77] Murtada S- Il, Mikush N, Wang M, Ren P, Kawamura Y, Ramachandra AB, et al. Lonafarnib improves cardiovascular function and survival in a mouse model of Hutchinson- ¬ Gilford progeria syndrome 2023:1–17.
[78] Dhillon S. Lonafarnib : First Approval. Drugs 2021. https://doi.org/10.1007/s40265-020-01464-z.
[79] Gordon LB, Kleinman ME, Massaro J, Ralph B, Sr DA, Shappell H, et al. HHS Public Access 2017;134:617–32. https://doi.org/10.1161/CIRCULATIONAHA.116.022188.Clinical.
[80] Guilbert SM, Nicolas L, Muchir A, Nissan X. Hutchinson-Gilford progeria syndrome : Rejuvenating old drugs to fight accelerated ageing 2023;190:3–12. https://doi.org/10.1016/j.ymeth.2020.04.005.
[81] Alomari S, Zhang I, Hernandez A, Kraft CY, Raj D, Kedda J, et al. Drug Repurposing for Glioblastoma and Current Advances in Drug Delivery — A Comprehensive Review of the Literature 2021.
[82] Kaushik I, Ramachandran S, Prasad S, Srivastava SK. Seminars in Cancer Biology Drug rechanneling : A novel paradigm for cancer treatment. Semin Cancer Biol 2021;68:279–90. https://doi.org/10.1016/j.semcancer.2020.03.011.
[83] Gills JJ, Lopiccolo J, Tsurutani J, Shoemaker RH, Best CJM, Abu-asab MS, et al. Cancer Therapy : Preclinical Nelfinavir , A Lead HIV Protease Inhibitor , Is a Broad-Spectrum , Anticancer Agent that Induces Endoplasmic Reticulum Stress , Autophagy , and Apoptosis In vitro and In vivo 2007;13:5183–94. https://doi.org/10.1158/1078-0432.CCR-07-0161.
[84] Tian X, Ye J, Alonso-basanta M, Hahn SM, Koumenis C, Dorsey JF. Modulation of CCAAT / Enhancer Binding Protein Homologous Protein ( CHOP ) -dependent DR5 Expression by Nelfinavir Sensitizes Glioblastoma Multiforme Cells to Tumor Necrosis Factor-related Apoptosis-inducing Ligand ( TRAIL ) * 2011;286:29408–16. https://doi.org/10.1074/jbc.M110.197665.
[85] Rufini A, Malisan F, Condò I, Testi R. Drug Repositioning in Friedreich Ataxia 2022;16:1–15. https://doi.org/10.3389/fnins.2022.814445.
[86] Franceschin L, Guidotti A, Mazzetto R, Tartaglia J, Ciolfi C. Repurposing Historic Drugs for Neutrophil-Mediated Inflammation in Skin Disorders 2024.
[87] Katz J, Langevitz P, Shemer J, Barak S. Prevention of recurrent aphthous stomatitis with colchicine : An open trial. J Am Acad Dermatol 1994;31:459–61. https://doi.org/10.1016/S0190-9622(94)70211-X.
[88] Fuentes J, Oliveira G, Albarran C, Ari Y Ben, Georgoula C, Pénélaud P. Bumetanide oral solution for the treatment of children and adolescents with autism spectrum disorder : Results from two randomized phase III studies 2023:2021–34. https://doi.org/10.1002/aur.3005.
[89] Fuchs C, Hoen PAC, Müller AR, Ehrhart F, Karnebeek CDM Van. Drug repurposing in Rett and Rett-like syndromes : a promising yet underrated opportunity ? 2024:1–9. https://doi.org/10.3389/fmed.2024.1425038.
[90] Egan CG. Use of carvedilol in hypertension : an update 2012:307–22.
[91] Jordan M, Schmidt K, Fuchs M, Just A, Pfanne A, Willmer L, et al. Repurposing of the carvedilol for treatment of the fi brotic lung 2025:1–13. https://doi.org/10.3389/fphar.2025.1534989.
[92] Porta EOJ, Kalesh K, Steel PG. Navigating drug repurposing for Chagas disease : advances , challenges , and opportunities 2023:1–20. https://doi.org/10.3389/fphar.2023.1233253.
[93] Haoying Yu, Shuyue Ren, Jingrong Wang, Tingting Lv LS& G Du. Bexarotene combined with lapatinib for the treatment of Cushing ’ s disease : evidence based on drug repositioning and experimental con fi rmation 2020:4–6. https://doi.org/10.1038/s41392-020-00284-7.
[94] Chen C, Wang C. TNF- a Blockade Inhibits Matrix Metalloproteinase 9 e Mediated Collagenase Activity in Stevens- Johnson Syndrome and Toxic Epidermal Necrolysis. Journal of Investigative Dermatology 2023;143:881–3. https://doi.org/10.1016/j.jid.2023.03.1652.
[95] Hiroyasu S, Turner CT, Richardson KC. Proteases in Pemphigoid Diseases 2019;10. https://doi.org/10.3389/fimmu.2019.01454.
[96] LUDWIG KB and RJ. Drug Development in Pemphigoid Diseases ( M 2020. https://doi.org/10.2340/00015555-3400.
[97] Ramos R, Vale N. Dual Drug Repurposing : The Example of Saracatinib 2024:1–13.
[98] Roark KM, If PH. Rapamycin for longevity : the pros , the cons , and future perspectives 2025:1–7. https://doi.org/10.3389/fragi.2025.1628187.
[99] Results FOP, Trial DP, Pignolo RJ, Baujat G, Hsiao EC, Keen R, et al. Palovarotene for Fibrodysplasia Ossi fi cans Progressiva 2022;37:1891–902. https://doi.org/10.1002/jbmr.4655.
[100] Hirbo Y, Tesfaye F, Jemal A. International Journal of Surgery Case Reports Fibrodysplasia Ossificans Progressiva : A rare disease due to unawareness , case report and literature review. Int J Surg Case Rep 2024;117:109548. https://doi.org/10.1016/j.ijscr.2024.109548.
[101] Ventura F, Williams E, Ikeya M, Bullock AN, Dijke P, Goumans M, et al. Challenges and Opportunities for Drug Repositioning in Fibrodysplasia Ossificans Progressiva 2021:1–22.
[102] Karaman Mayack B, Sippl W. Computational Drug Repurposing: Current Trends. Curr Med Chem 2018;25. https://doi.org/10.2174/0929867325666180530100332.
[103] Lin X, Li X, Lin X. A review on applications of computational methods in drug screening and design. Molecules 2020;25. https://doi.org/10.3390/molecules25061375.
[104] Cousins HC, Nayar G, Altman RB. Computational Approaches to Drug Repurposing: Methods, Challenges, and Opportunities. Annual Review of Biomedical Data Science Downloaded from WwwAnnualreviewsOrg Guest 2025;34:40. https://doi.org/10.1146/annurev-biodatasci-110123.
[105] Yadav MK, Dahiya V, Tripathi MK, Chaturvedi N, Rashmi M, Ghosh A, et al. Unleashing the future: The revolutionary role of machine learning and artificial intelligence in drug discovery. Eur J Pharmacol 2024;985:177103. https://doi.org/https://doi.org/10.1016/j.ejphar.2024.177103.
[106] Ghandikota SK, Jegga AG. Application of artificial intelligence and machine learning in drug repurposing, 2024, p. 171–211. https://doi.org/10.1016/bs.pmbts.2024.03.030.
[107] Jiang W, Ye W, Tan X, Bao YJ. Network-based multi-omics integrative analysis methods in drug discovery: a systematic review. BioData Min 2025;18. https://doi.org/10.1186/s13040-025-00442-z.
[108] Ahmed F, Soomro AM, Chethikkattuveli Salih AR, Samantasinghar A, Asif A, Kang IS, et al. A comprehensive review of artificial intelligence and network based approaches to drug repurposing in Covid-19. Biomedicine & Pharmacotherapy 2022;153:113350. https://doi.org/10.1016/j.biopha.2022.113350.
[109] Rodrigues D, Souza T, Jennen DGJ, Lemmens L, Kleinjans JCS, de Kok TM. Drug-induced gene expression profile changes in relation to intestinal toxicity: State-of-the-art and new approaches. Cancer Treat Rev 2019;77:57–66. https://doi.org/https://doi.org/10.1016/j.ctrv.2019.06.004.
[110] Aliper A, Plis S, Artemov A, Ulloa A, Mamoshina P, Zhavoronkov A. Deep Learning Applications for Predicting Pharmacological Properties of Drugs and Drug Repurposing Using Transcriptomic Data. Mol Pharm 2016;13:2524–30. https://doi.org/10.1021/acs.molpharmaceut.6b00248.
[111] Chen H, Engkvist O, Wang Y, Olivecrona M, Blaschke T. The rise of deep learning in drug discovery. Drug Discov Today 2018;23:1241–50. https://doi.org/https://doi.org/10.1016/j.drudis.2018.01.039.
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2026 Michael Ibrahim Boushra, Fatema H. Hussein, Arwa M. Mansour, Doha O. El Bagory, Rawan Alaa, Radwa Waleed, Khadeeja A. Mamdouh, Esraa M. Abdelhalim, May A. El-Manawaty
This work is licensed under a Creative Commons Attribution 4.0 International License.
